|Videos|September 22, 2017

What Makes ABSSSI Antibiotic Iclaprim Unique?

Author(s)Contagion&reg Editorial Staff

William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.

William D. O’Riordan, MD, FACEP, chief medical officer, eStudySite, explains how iclaprim has a unique mechanism of action, making it a unique antibiotic to treat acute bacterial skin and skin structure infections. Dr. O’Riordan explains how dihydrofolate reductase interferes with an enzyme that is involved with the bacterial cell and essentially “does away” with it.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 9th, 2026

New UTI Guidelines: Addressing the Shift to Localized, Systemic Infection Classification

UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.

October 1st, 2026

Further Insights, Treatment Considerations Around the PETERPEN Study

Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.

October 4th, 2026

Recent Guideline Updates in the Management of Urinary Tract Infections

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.

October 2nd, 2026

Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization

Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.

October 1st, 2026

New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework

IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.

September 28th, 2026

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

September 28th, 2026

On World Rabies Day, When to Seek Treatment, Clinical Considerations for Post Exposure Prophylaxis

With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.

September 26th, 2026

Environmental Stewardship: The Role of Antimicrobials in Climate Change

Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.

What Makes ABSSSI Antibiotic Iclaprim Unique?

Newsletter

Related to this article